Deciding whether to purchase shares of CG Oncology (NASDAQ: CGON) requires evaluating your personal risk tolerance, investment horizon, and comfort level with the biotechnology sector. Wall Street equity research analysts currently maintain an overwhelmingly optimistic outlook on the stock, issuing a consensus "Strong Buy" rating with an average 12-month price target significantly above its current trading levels. The bullish thesis centers around the company's lead oncolytic immunotherapy candidate, cretostimogene grenadenorepvec, which targets high-risk non-muscle-invasive bladder cancer. Proponents highlight robust clinical trial progression, a healthy balance sheet extending operational runway, and unique market positioning. Conversely, bear cases emphasize typical biotech vulnerabilities, including regulatory review delays, trial outcome risks, potential competitive pressures, and the inherent volatility of clinical-stage pharmaceutical equities. Comprehensive personal due diligence or consultation with a certified financial advisor is strongly recommended before committing capital.
Yes, you can say "arigato", but it is important to understand its social register before using it in conversation. Arigato translates to "thank you," but it is an informal and casual expression. Native Japanese speakers use it comfortably with close friends, family members, peers, or younger individuals. However, using arigato by itself to strangers, senior colleagues, business clients, or authority figures can come across as overly casual or rude because it lacks the polite honorific suffix gozaimasu. In professional, formal, or polite settings, etiquette strictly dictates using the complete phrase arigato gozaimasu to show proper respect and maintain smooth interpersonal relations.